OncoSec Medical Inc (ONCSQ)

[jondoeuk]

I can't see that happening. $BMY made a deal worth up to $3.6B with $NKTR for certain rights to NKTR-214. They have an exclusive development period to pursue a broad combo development program covering 20 indications involving 9 tumours (Non-Small Cell Lung, Small Cell Lung, Melanoma, Renal Cell Carcinoma, Urothelial, Breast, Colorectal, Gastric and Sarcoma), matching 214 with Opdivo and/or Yervoy.

The ongoing PIVOT trial is using 214 and Opdivo in Melanoma, RCC, NSCLC,
Bladder, TNBC, Colorectal, Gastric and SCLC. In addition to that two Phase 3 trials in 1L Melanoma and 1L Renal Cell Carcicoma are to start sometime this year. Also $BMY bought IFM Therapeutics (up to $2.3B) for it's STING https://cen.acs.org/articles/96/i9/STING-fever-sweeping-through-cancer.html and NLRP3 agonist programs.